Clinical Trial Update: Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma [EARLY_Phase 1]

View source ↗

Summary

A phase 1 trial is evaluating the combination of pembrolizumab and lenvatinib for advanced, unresectable, or metastatic gastric cancer and gastroesophageal junc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | EARLY_Phase 1 | Status: RECRUITING